Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDX-010 in metastatic melanoma
NCT00050102Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2002
- Primary completion
- Feb 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised trial of ipilimumab in melanoma (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Safety and Tolerability Profile. Started Oct 2002; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00050102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050102.